Vertex Pharmaceutic (VRTX)

$430.29 -4.81 (-1.11%)
Market Cap 110.67B
Revenue (ttm) 12.00B
Net Income (ttm) 3.95B
EPS (ttm) N/A
PE Ratio 26.65
Forward PE 26.09
Profit Margin 32.94%
Debt to Equity Ratio 0.00
Volume 1,128,000
Avg Vol 1,360,938
Day's Range N/A - N/A
Shares Out 254.36M
Stochastic %K 14%
Beta 0.36
Analysts Strong Sell
Price Target $550.39

Company Profile

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for peo...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 341 6100
Address:
50 Northern Avenue, Boston, United States
FlowCapitalStudio
FlowCapitalStudio Apr. 25 at 5:49 AM
$VRTX biotech leader supported by strong pipeline execution and premium profitability
0 · Reply
Biologics
Biologics Apr. 22 at 10:14 AM
My recent $VRTX article. https://seekingalpha.com/article/4892721-vertex-pharmaceuticals-looking-for-signs-of-success-in-q1-earnings?source=copy_to_clipboard
0 · Reply
3D_STOCK_TRADING
3D_STOCK_TRADING Apr. 21 at 10:27 PM
$VRTX Vertex needs to buy Sernova... Before some other company does!!! Its our lifeline.
0 · Reply
ihuntbiggame
ihuntbiggame Apr. 20 at 3:47 PM
$VUZI Connect more DOTS... Mr. YUTAKA, what a good looking suit & wish I still had all that hair! $HIMS? We can assume...these 3 dots are going to be released... MUFAM is a major institutional lender and investor in the pharmaceutical and medical equipment sectors. These companies use AR for remote surgical assistance, medical training, and pharmaceutical manufacturing quality control. Vertex Pharmaceuticals ($VRTX): MUFAM increased its stake in Vertex Pharmaceuticals to over 544,000 shares (valued at ~$213M) in early 2026. Vuzix tech is used in high-stakes biotech labs for hands-free data visualization during drug discovery and manufacturing processes. STERIS plc ($STE): MUFAM holds over 1.5M shares (~$387M) in STERIS, a leader in sterilization and surgical equipment. Smart glasses are used in sterile processing departments to provide step-by-step digital workflows for technicians cleaning complex surgical instruments.
2 · Reply
pilobious
pilobious Apr. 20 at 1:57 PM
$VRTX kidney drug must be all hype. Down from $500 since the announcement. I’m long but disappointed.
3 · Reply
parcha
parcha Apr. 18 at 12:12 PM
Cramer's lightning round: Buy Vertex Pharmaceuticals $VRTX Vertex Pharmaceuticals: “I think Vertex is very strong. I wish I had bought it for the Charitable Trust a long time ago when we had the CEO on. It was an excellent call, and then I got cold feet. That was a mistake. It’s a good buy.” https://www.cnbc.com/2026/04/17/cramers-lightning-round-buy-vertex-pharmaceuticals.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
svertical1
svertical1 Apr. 18 at 12:53 AM
$VRTX Good to see! Now lower price, and sell Billions!
0 · Reply
dens214
dens214 Apr. 17 at 7:12 PM
$VRTX besides money what else does vertex make?
0 · Reply
jcooptechit
jcooptechit Apr. 16 at 4:06 PM
$CELZ UPTREND CONFIRMED AND $2.32 IS THE LAUNCHPAD CELZ has flipped bullish with higher lows and is now pressing a key breakout zone. 📊 Levels: ▫️ Demand: $1.95 – $2.05 (strong base) ▫️ Support: $2.10 – $2.20 ▫️ Pivot: $2.32: key level ▫️ Resistance: $2.50 → $2.72 📈 Structure tightening + momentum building: → Hold & push $2.32 → opens move to $2.50 / $2.72 → Break $2.72 → $3+ comes into play FAST → Backed by ongoing trials + upcoming clinical updates = catalyst fuel 👀 Watching closely as this is where momentum traders often step in. Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers: $REGN $VRTX $ALNY $IONS
0 · Reply
jcooptechit
jcooptechit Apr. 16 at 1:33 PM
$CELZ AT A CLINICAL INFLECTION POINT AND DATA + MOMENTUM ALIGNING CELZ isn’t just a story anymore… it’s showing real clinical progress. 🧬 CELZ-201 (Back Pain | ADAPT Trial): ▫️ Phase I/II COMPLETE enrollment ▫️ Positive 180-day data ▫️ 79% patient improvement ▫️ No major safety concerns ▫️ FDA Fast Track Now entering data maturation + next-stage pathway 💥 THE ALPHA: ✅ Early efficacy ✅ Safety validated ✅ Massive market (chronic back pain) This is where small-cap biotech names can rerate FAST. Next catalysts: final data + regulatory progress + potential partnerships. 👀 Clinical validation + technical setup = one to watch closely Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers/ Competitors: $MESO $VRTX $NVAX $MRNA
1 · Reply
Latest News on VRTX
Vertex to Announce First Quarter 2026 Financial Results on May 4th

Apr 6, 2026, 4:00 PM EDT - 18 days ago

Vertex to Announce First Quarter 2026 Financial Results on May 4th

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

Apr 1, 2026, 7:30 AM EDT - 24 days ago

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 5 weeks ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results

Mar 10, 2026, 1:22 PM EDT - 6 weeks ago

This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results

Vertex passes key test In quest to treat kidney diseases

Mar 10, 2026, 10:54 AM EDT - 6 weeks ago

Vertex passes key test In quest to treat kidney diseases

Vertex's kidney disease drug meets main goal in late-stage trial

Mar 9, 2026, 4:13 PM EDT - 6 weeks ago

Vertex's kidney disease drug meets main goal in late-stage trial

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

Mar 9, 2026, 4:02 PM EDT - 6 weeks ago

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

Vertex to Participate in Upcoming March Investor Conferences

Mar 5, 2026, 4:00 PM EST - 7 weeks ago

Vertex to Participate in Upcoming March Investor Conferences

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

Mar 5, 2026, 10:00 AM EST - 7 weeks ago

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

Feb 17, 2026, 4:00 PM EST - 2 months ago

Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments

Feb 12, 2026, 4:06 PM EST - 2 months ago

Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 12, 2026, 4:01 PM EST - 2 months ago

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

Feb 2, 2026, 10:08 PM EST - 2 months ago

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil

Jan 22, 2026, 1:19 PM EST - 3 months ago

Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil

KMB XOM SPGI

Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

Jan 20, 2026, 4:00 PM EST - 3 months ago

Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Jan 11, 2026, 5:00 PM EST - 3 months ago

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12

Dec 22, 2025, 4:00 PM EST - 4 months ago

Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12

Vertex's gene therapy shows promise in younger children with blood disorders

Dec 6, 2025, 7:04 AM EST - 4 months ago

Vertex's gene therapy shows promise in younger children with blood disorders

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

Dec 6, 2025, 7:01 AM EST - 4 months ago

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3

Nov 19, 2025, 4:00 PM EST - 5 months ago

Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Nov 8, 2025, 5:15 PM EST - 5 months ago

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Committee stocks on the move: Uber and Vertex Pharma

Nov 4, 2025, 1:22 PM EST - 6 months ago

Committee stocks on the move: Uber and Vertex Pharma

UBER

Vertex beats quarterly estimates on cystic fibrosis demand, new drugs

Nov 3, 2025, 4:20 PM EST - 6 months ago

Vertex beats quarterly estimates on cystic fibrosis demand, new drugs

Vertex Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 4:02 PM EST - 6 months ago

Vertex Reports Third Quarter 2025 Financial Results

Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Nov 3, 2025, 2:23 PM EST - 6 months ago

Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Vertex to Participate in the UBS Global Healthcare Conference on November 11

Oct 27, 2025, 4:00 PM EDT - 6 months ago

Vertex to Participate in the UBS Global Healthcare Conference on November 11

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

Oct 23, 2025, 9:00 AM EDT - 6 months ago

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

Oct 17, 2025, 9:04 AM EDT - 6 months ago

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

Oct 6, 2025, 4:00 PM EDT - 7 months ago

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR

Oct 2, 2025, 1:31 PM EDT - 7 months ago

Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR

IJR NOW

Vertex Announces Key Advancements Across Kidney Portfolio

Sep 25, 2025, 7:45 AM EDT - 7 months ago

Vertex Announces Key Advancements Across Kidney Portfolio

Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain

Sep 23, 2025, 9:00 AM EDT - 7 months ago

Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy

Sep 18, 2025, 8:30 AM EDT - 7 months ago

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy

Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis

Sep 11, 2025, 9:05 AM EDT - 8 months ago

Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis

Calls of the Day: Abbvie, Vertex, Veeva and Vistra

Sep 8, 2025, 1:47 PM EDT - 8 months ago

Calls of the Day: Abbvie, Vertex, Veeva and Vistra

ABBV VEEV VST

Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases

Sep 2, 2025, 9:00 AM EDT - 8 months ago

Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases

Vertex to Participate in Upcoming September Investor Conferences

Aug 20, 2025, 4:00 PM EDT - 8 months ago

Vertex to Participate in Upcoming September Investor Conferences

Weakness In Vertex Stock Seen As Buying Opportunity

Aug 5, 2025, 2:05 PM EDT - 9 months ago

Weakness In Vertex Stock Seen As Buying Opportunity

These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results

Aug 5, 2025, 1:58 PM EDT - 9 months ago

These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results

Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug

Aug 5, 2025, 10:25 AM EDT - 9 months ago

Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug

Inspire Medical Systems, Ichor Holdings, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Aug 5, 2025, 8:09 AM EDT - 9 months ago

Inspire Medical Systems, Ichor Holdings, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

ICHR INSP

Vertex tops estimates on cystic fibrosis treatment strength, new products

Aug 4, 2025, 5:40 PM EDT - 9 months ago

Vertex tops estimates on cystic fibrosis treatment strength, new products

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings

Aug 4, 2025, 5:13 PM EDT - 9 months ago

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings

Vertex Pharmaceuticals reports earnings, beating EPS, revenue estimates

Aug 4, 2025, 4:59 PM EDT - 9 months ago

Vertex Pharmaceuticals reports earnings, beating EPS, revenue estimates

Vertex to stop developing new painkiller as solo treatment after mid-stage study setback

Aug 4, 2025, 4:24 PM EDT - 9 months ago

Vertex to stop developing new painkiller as solo treatment after mid-stage study setback

Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain

Aug 4, 2025, 4:01 PM EDT - 9 months ago

Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain

Vertex Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 4:01 PM EDT - 9 months ago

Vertex Reports Second Quarter 2025 Financial Results

Vertex Pharmaceuticals Likely To Report Q2 Profit; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Aug 4, 2025, 1:48 PM EDT - 9 months ago

Vertex Pharmaceuticals Likely To Report Q2 Profit; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

How Will VRTX Stock React To Its Upcoming Earnings?

Aug 2, 2025, 12:20 AM EDT - 9 months ago

How Will VRTX Stock React To Its Upcoming Earnings?

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 9 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

FlowCapitalStudio
FlowCapitalStudio Apr. 25 at 5:49 AM
$VRTX biotech leader supported by strong pipeline execution and premium profitability
0 · Reply
Biologics
Biologics Apr. 22 at 10:14 AM
My recent $VRTX article. https://seekingalpha.com/article/4892721-vertex-pharmaceuticals-looking-for-signs-of-success-in-q1-earnings?source=copy_to_clipboard
0 · Reply
3D_STOCK_TRADING
3D_STOCK_TRADING Apr. 21 at 10:27 PM
$VRTX Vertex needs to buy Sernova... Before some other company does!!! Its our lifeline.
0 · Reply
ihuntbiggame
ihuntbiggame Apr. 20 at 3:47 PM
$VUZI Connect more DOTS... Mr. YUTAKA, what a good looking suit & wish I still had all that hair! $HIMS? We can assume...these 3 dots are going to be released... MUFAM is a major institutional lender and investor in the pharmaceutical and medical equipment sectors. These companies use AR for remote surgical assistance, medical training, and pharmaceutical manufacturing quality control. Vertex Pharmaceuticals ($VRTX): MUFAM increased its stake in Vertex Pharmaceuticals to over 544,000 shares (valued at ~$213M) in early 2026. Vuzix tech is used in high-stakes biotech labs for hands-free data visualization during drug discovery and manufacturing processes. STERIS plc ($STE): MUFAM holds over 1.5M shares (~$387M) in STERIS, a leader in sterilization and surgical equipment. Smart glasses are used in sterile processing departments to provide step-by-step digital workflows for technicians cleaning complex surgical instruments.
2 · Reply
pilobious
pilobious Apr. 20 at 1:57 PM
$VRTX kidney drug must be all hype. Down from $500 since the announcement. I’m long but disappointed.
3 · Reply
parcha
parcha Apr. 18 at 12:12 PM
Cramer's lightning round: Buy Vertex Pharmaceuticals $VRTX Vertex Pharmaceuticals: “I think Vertex is very strong. I wish I had bought it for the Charitable Trust a long time ago when we had the CEO on. It was an excellent call, and then I got cold feet. That was a mistake. It’s a good buy.” https://www.cnbc.com/2026/04/17/cramers-lightning-round-buy-vertex-pharmaceuticals.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
svertical1
svertical1 Apr. 18 at 12:53 AM
$VRTX Good to see! Now lower price, and sell Billions!
0 · Reply
dens214
dens214 Apr. 17 at 7:12 PM
$VRTX besides money what else does vertex make?
0 · Reply
jcooptechit
jcooptechit Apr. 16 at 4:06 PM
$CELZ UPTREND CONFIRMED AND $2.32 IS THE LAUNCHPAD CELZ has flipped bullish with higher lows and is now pressing a key breakout zone. 📊 Levels: ▫️ Demand: $1.95 – $2.05 (strong base) ▫️ Support: $2.10 – $2.20 ▫️ Pivot: $2.32: key level ▫️ Resistance: $2.50 → $2.72 📈 Structure tightening + momentum building: → Hold & push $2.32 → opens move to $2.50 / $2.72 → Break $2.72 → $3+ comes into play FAST → Backed by ongoing trials + upcoming clinical updates = catalyst fuel 👀 Watching closely as this is where momentum traders often step in. Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers: $REGN $VRTX $ALNY $IONS
0 · Reply
jcooptechit
jcooptechit Apr. 16 at 1:33 PM
$CELZ AT A CLINICAL INFLECTION POINT AND DATA + MOMENTUM ALIGNING CELZ isn’t just a story anymore… it’s showing real clinical progress. 🧬 CELZ-201 (Back Pain | ADAPT Trial): ▫️ Phase I/II COMPLETE enrollment ▫️ Positive 180-day data ▫️ 79% patient improvement ▫️ No major safety concerns ▫️ FDA Fast Track Now entering data maturation + next-stage pathway 💥 THE ALPHA: ✅ Early efficacy ✅ Safety validated ✅ Massive market (chronic back pain) This is where small-cap biotech names can rerate FAST. Next catalysts: final data + regulatory progress + potential partnerships. 👀 Clinical validation + technical setup = one to watch closely Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers/ Competitors: $MESO $VRTX $NVAX $MRNA
1 · Reply
JFais
JFais Apr. 16 at 1:21 PM
$TVTX- had to rain on the parade didn't you @adamfeuerstein 😉 Good news $TVTX will build out the FSGS market and better treatments will follow (CCR2 blocker DMX-200 & complement inhibitors like $APLS $BIIB Empaveli in P3, BAFF APRIL a la atacicept & $VRTX poveticacicept, etc)
0 · Reply
kareem1988
kareem1988 Apr. 16 at 9:28 AM
April is proving to be a powerhouse month for select biotech names. These four have been stacking green days and showing relentless momentum: $DRTS The clear leader this month. Riding a massive green streak as anticipation builds for the upcoming pancreatic cancer data at DDW. $VRTX Consistent upward grind. Big money is treating this as a safe haven while the pipeline continues to deliver. $REGN Strong recovery trend throughout April. Technicals look great as it reclaimed key moving averages on steady buying. $CPRX Quietly outperforming with nearly daily gains. Solid fundamental strength is keeping the bid under this one. These are trending right now, Watching to see if these four can carry this strength into May.
4 · Reply
hustledad
hustledad Apr. 15 at 10:23 PM
$VRTX
0 · Reply
hustledad
hustledad Apr. 15 at 7:14 PM
$TNXP I can’t help but wish for a buyout offer from $VRTX . They have tons of cash, our drug Tonmya complements their pain management non-opioid med Journavx - which is starting to be de facto med for post-surgery. Might be a long shot but I hope it happens.
1 · Reply
JFais
JFais Apr. 15 at 3:56 PM
Plot twist: $RVMD becomes the next serial acquirer in biotech (after doing for PDAC what $VRTX did for CF patients)
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 14 at 10:39 AM
$VRTX Share Price: $440.01 Contract Selected: May 08, 2026 $440 Calls Buy Zone: $14.23 – $17.58 Target Zone: $23.24 – $28.41 Potential Upside: 54% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Wischmop
Wischmop Apr. 13 at 2:33 PM
$ABBV $SGMO $VRTX Why not buy the cow that promises painless dreams? Things could get interesting again in the final days…
0 · Reply
biotech
biotech Apr. 13 at 2:02 PM
$SGMO ... $ABBV AbbVie enters world of #pain in up to $715M deal with China’s Haisco "Haisco has previously presented preclinical data on NaV1.8 inhibitors" re $SGMO NAV1.7 "multiple pot. partners" $VRTX $ABBV .... .... https://www.biospace.com/business/abbvie-enters-world-of-pain-in-up-to-715m-deal-with-chinas-haisco
1 · Reply
AXLFI_HQ
AXLFI_HQ Apr. 11 at 2:19 PM
$VRTX Clinical-stage and specialty therapeutics companies filing for IPOs, signaling investor appetite for healthcare innovation and regulatory pathway validation. Learn more: https://axlfi.com/themes/67
0 · Reply
kamenrider888
kamenrider888 Apr. 11 at 7:30 AM
$VRTX mildly bullish.. HOLD...
0 · Reply
profitcatcher
profitcatcher Apr. 9 at 7:43 AM
$VRTX Vertex is the king of cystic fibrosis, but the real story is their pain management pipeline and CRISPR partnership. They have a massive cash pile to fund M&A. The technicals are breaking out of a multi-year base. I'm long for the expansion into non-opioid pain relief. This is a rare biotech with a massive moat and high growth.
1 · Reply
DonCorleone77
DonCorleone77 Apr. 8 at 4:16 PM
$VRTX Attached is page 1 of a Oppenheimer analyst report regarding VRTX issued yesterday.
3 · Reply